首页 > 最新文献

American journal of clinical and experimental immunology最新文献

英文 中文
Melanocortin-4 receptor in subthalamic nucleus is involved in the modulation of nociception. 丘脑下核黑素皮质素-4受体参与伤害感觉的调节。
Q4 IMMUNOLOGY Pub Date : 2018-08-20 eCollection Date: 2018-01-01
Dong-Ji Han, Zhi-Gang He, Hui Yang

Deep brain stimulation of the subthalamic nucleus (STN-DBS) stimulation produces significant improvement of overall pain related to Parkinson disease; however, the mechanisms underlying analgesic effects of STN-DBS are still unknown. This report describes direct neuroanatomical evidence for the central melanocortinergic-opioidergic circuits in the STN. We investigated melanocortin-4 receptor (MC4R) and mu-opioid receptor (MOR)-positive expression of the STN in MC4R-GFP transgenic mice using fluorescence immunohistochemical detection. Immunohistochemistry showed a large number of MC4R-GFP- and MOR-positive neurons within the STN region, and approximately 50% of MC4R-GFP-positive neurons coexpressed MOR. The results of this study showed direct neuroanatomical evidence for the central melanocortinergic-opioidergic signaling in the STN region. These findings contribute to the view of melanocortinergic-opioidergic circuits in the subthalamic nucleus as a reliable source of modulating of nociception with therapeutic potential for alleviating pain.

丘脑底核深部脑刺激(STN-DBS)刺激可显著改善帕金森病相关的整体疼痛;然而,STN-DBS镇痛作用的机制尚不清楚。本报告描述了STN中中枢黑素皮质能-阿片能回路的直接神经解剖学证据。采用荧光免疫组化方法研究了MC4R- gfp转基因小鼠中黑素皮质素-4受体(melanocortin-4 receptor, MC4R)和阿片受体(mua -opioid receptor, MOR) STN的阳性表达。免疫组化显示STN区有大量MC4R-GFP和MOR阳性神经元,约50%的MC4R-GFP阳性神经元共表达MOR。本研究结果为STN区域的中枢黑素皮质能-阿片能信号传导提供了直接的神经解剖学证据。这些发现有助于认为,丘脑下核中的黑素皮质能-阿片能回路是调节伤害感觉的可靠来源,具有减轻疼痛的治疗潜力。
{"title":"Melanocortin-4 receptor in subthalamic nucleus is involved in the modulation of nociception.","authors":"Dong-Ji Han,&nbsp;Zhi-Gang He,&nbsp;Hui Yang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Deep brain stimulation of the subthalamic nucleus (STN-DBS) stimulation produces significant improvement of overall pain related to Parkinson disease; however, the mechanisms underlying analgesic effects of STN-DBS are still unknown. This report describes direct neuroanatomical evidence for the central melanocortinergic-opioidergic circuits in the STN. We investigated melanocortin-4 receptor (MC4R) and mu-opioid receptor (MOR)-positive expression of the STN in MC4R-GFP transgenic mice using fluorescence immunohistochemical detection. Immunohistochemistry showed a large number of MC4R-GFP- and MOR-positive neurons within the STN region, and approximately 50% of MC4R-GFP-positive neurons coexpressed MOR. The results of this study showed direct neuroanatomical evidence for the central melanocortinergic-opioidergic signaling in the STN region. These findings contribute to the view of melanocortinergic-opioidergic circuits in the subthalamic nucleus as a reliable source of modulating of nociception with therapeutic potential for alleviating pain.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"7 4","pages":"76-80"},"PeriodicalIF":0.0,"publicationDate":"2018-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146155/pdf/ajcei0007-0076.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36517626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of allergic stimulation and glucocorticoids on miR-155 in CD4+ T-cells. 过敏刺激和糖皮质激素对CD4+T细胞中miR-155的影响。
Q4 IMMUNOLOGY Pub Date : 2018-08-20 eCollection Date: 2018-01-01
Elizabeth Daniel, Alanna Roff, Man-Hsun Hsu, Ronaldo Panganiban, Kristin Lambert, Faoud Ishmael

Rationale: MicroRNAs (miRNAs) are emerging as important regulators of allergic inflammation and potential therapeutic targets. We sought to identify which miRNAs are expressed in CD4+ T-cells and determine whether allergic stimuli or glucocorticoids alter their expression.

Methods: After IRB approval, blood was collected from dust mite (DM) allergic rhinitis subjects (n=20), non-allergic controls (n=8), and asthmatics (n=16). Peripheral blood mononuclear cells were incubated with dust mite extract (DME), diluent control, or DME + dexamethasone (0.1 µM). CD4+ T-cells were collected by magnetic bead column, and RNA was isolated by guanidinium/phenol-chloroform extraction. MicroRNA expression was measured using Nanostring microarray and quantitative real time PCR (qPCR).

Results: We identified 196 miRNAs that were stably expressed in circulating CD4+ T-cells. Allergen stimulation of CD4+ T-cells with DME differentially induced miR-155 expression in cells of DM-allergic subjects as compared to non-allergic subjects. Induction of miR-155 expression was also observed with anti-CD3/anti-CD28 simulation and phorbol-12-Myristate-13-Acetate (PMA) treatment, and further augmented by calcium inophore and bromocyclic AMP in the latter treatment. The level of miR-155 expression was positively associated with expression of the TH2 cytokines IL-5 and IL-13. Inhibition of miR-155 in Jurkat T-cells inhibited the production of these cytokines. Glucocorticoids attenuated the effects of dust mite allergen, raising the possibility that inhibition of this miRNA could be a mechanism through which glucocorticoids exhibit their anti-inflammatory effects. The CD4+ T-cells had a higher level of miR-155 expression in asthma compared to in allergic rhinitis and non-asthmatics. The inhibitory effects of glucocorticoids on CD4+ T-cell miR-155 expression were lost in severe asthmatics.

Conclusion: Mir-155 is differentially expressed in allergic T-cells exposed to DM extract compared to in non-allergic cells and it is inhibited by glucocorticoids. MiR-155 may play a role in mediating allergic inflammation in T-cells and could be an anti-inflammatory target of steroids. This pathway may be de-regulated in severe asthma.

理由:微小RNA(miRNA)正在成为过敏性炎症的重要调节因子和潜在的治疗靶点。我们试图确定哪些miRNA在CD4+T细胞中表达,并确定过敏刺激或糖皮质激素是否改变了它们的表达。方法:在IRB批准后,从尘螨(DM)过敏性鼻炎受试者(n=20)、非过敏性对照者(n=8)和哮喘患者(n=16)中采集血液。外周血单核细胞与尘螨提取物(DME)、稀释剂对照或DME+地塞米松(0.1µM)一起孵育。通过磁珠柱收集CD4+T细胞,并通过胍/苯酚-氯仿提取分离RNA。结果:我们鉴定出196个miRNA在循环CD4+T细胞中稳定表达。与非过敏性受试者相比,用DME刺激CD4+T细胞的过敏原在DM过敏受试者的细胞中差异诱导miR-155表达。用抗CD3/抗CD28模拟和佛波醇-12-嘧啶酸盐13-乙酸酯(PMA)处理也观察到miR-155表达的诱导,并在后一种处理中通过无孔钙和溴环AMP进一步增强。miR-155的表达水平与TH2细胞因子IL-5和IL-13的表达呈正相关。Jurkat T细胞中miR-155的抑制抑制了这些细胞因子的产生。糖皮质激素减弱了尘螨过敏原的作用,增加了抑制这种miRNA可能是糖皮质激素发挥抗炎作用的机制的可能性。CD4+T细胞在哮喘中的miR-155表达水平高于过敏性鼻炎和非哮喘患者。糖皮质激素对CD4+T细胞miR-155表达的抑制作用在严重哮喘患者中消失。结论:Mir-155在暴露于DM提取物的过敏性T细胞中与非过敏性细胞相比有差异表达,并且受到糖皮质激素的抑制。MiR-155可能在介导T细胞的过敏性炎症中发挥作用,并且可能是类固醇的抗炎靶点。这种途径可能在严重哮喘中被解除调节。
{"title":"Effects of allergic stimulation and glucocorticoids on miR-155 in CD4<sup>+</sup> T-cells.","authors":"Elizabeth Daniel, Alanna Roff, Man-Hsun Hsu, Ronaldo Panganiban, Kristin Lambert, Faoud Ishmael","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Rationale: </strong>MicroRNAs (miRNAs) are emerging as important regulators of allergic inflammation and potential therapeutic targets. We sought to identify which miRNAs are expressed in CD4<sup>+</sup> T-cells and determine whether allergic stimuli or glucocorticoids alter their expression.</p><p><strong>Methods: </strong>After IRB approval, blood was collected from dust mite (DM) allergic rhinitis subjects (n=20), non-allergic controls (n=8), and asthmatics (n=16). Peripheral blood mononuclear cells were incubated with dust mite extract (DME), diluent control, or DME + dexamethasone (0.1 µM). CD4<sup>+</sup> T-cells were collected by magnetic bead column, and RNA was isolated by guanidinium/phenol-chloroform extraction. MicroRNA expression was measured using Nanostring microarray and quantitative real time PCR (qPCR).</p><p><strong>Results: </strong>We identified 196 miRNAs that were stably expressed in circulating CD4<sup>+</sup> T-cells. Allergen stimulation of CD4<sup>+</sup> T-cells with DME differentially induced miR-155 expression in cells of DM-allergic subjects as compared to non-allergic subjects. Induction of miR-155 expression was also observed with anti-CD3/anti-CD28 simulation and phorbol-12-Myristate-13-Acetate (PMA) treatment, and further augmented by calcium inophore and bromocyclic AMP in the latter treatment. The level of miR-155 expression was positively associated with expression of the T<sub>H</sub>2 cytokines IL-5 and IL-13. Inhibition of miR-155 in Jurkat T-cells inhibited the production of these cytokines. Glucocorticoids attenuated the effects of dust mite allergen, raising the possibility that inhibition of this miRNA could be a mechanism through which glucocorticoids exhibit their anti-inflammatory effects. The CD4<sup>+</sup> T-cells had a higher level of miR-155 expression in asthma compared to in allergic rhinitis and non-asthmatics. The inhibitory effects of glucocorticoids on CD4<sup>+</sup> T-cell miR-155 expression were lost in severe asthmatics.</p><p><strong>Conclusion: </strong>Mir-155 is differentially expressed in allergic T-cells exposed to DM extract compared to in non-allergic cells and it is inhibited by glucocorticoids. MiR-155 may play a role in mediating allergic inflammation in T-cells and could be an anti-inflammatory target of steroids. This pathway may be de-regulated in severe asthma.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"7 4","pages":"57-66"},"PeriodicalIF":0.0,"publicationDate":"2018-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146153/pdf/ajcei0007-0057.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Induction therapy downregulates the expression of Th17/Tfh cytokines in patients with active lupus nephritis. 诱导治疗下调活动性狼疮性肾炎患者Th17/Tfh细胞因子的表达。
Q4 IMMUNOLOGY Pub Date : 2018-08-20 eCollection Date: 2018-01-01
Na Wang, Congcong Gao, Siwan Cui, Yilu Qin, Chunyi Zhang, Peiwen Yi, Xueqi Di, Shengyun Liu, Tianfang Li, Guanmin Gao, Zhaohui Zheng

To determine the potential changes of IL-6, IL-17A and IL-21 levels during induction therapy, and to assess their relationship with disease activity and immunologic features on patients with active lupus nephritis, twenty-eight patients treated with corticosteroid and immunosuppressants were included in this study. Demographic, clinical, serological data and disease activity were assessed. Blood samples were collected at week 0, 12 and 24, and serum concentrations of IL-17A, IL-6 and IL-21 were measured by cytometric bead array. The serum concentrations of IL-6, IL-17A and IL-21 (P<0.001, P<0.01, P=0.001, respectively) decreased progressively during induction therapy. Concentration of IL-6, IL-17A and IL-21 was higher in non-remission group than that in remission group. A positive correlation was established between the concentration of these cytokines and the severity of proteinuria (P<0.001, P=0.020, P=0.045, respectively), ESR (P<0.001), SLEDAI scores (P<0.05), and ANA titers (P=0.018, P=0.048, P<0.05, respectively). Additionally, ROC curve analysis for IL-6, IL-17A and IL-21 was performed to predict the disease activity. The optimal cutoff level was 5.78 pg/ml, 1.98 pg/ml and 8.59 pg/ml, with AUC=0.809, 0.735 and 0.786. The concentration of IL-6 and IL-21 may be regarded as an indicator for the remission of active lupus nephritis, with cutoff value of 9.12 pg/ml and 11.30 pg/ml, while AUC=0.930 and 0.896. The production of serum IL-6, IL-17A and IL-21 in active LN was dramatically declined during induction therapy, which may improve disease activity while delay disease progression of LN.

为了确定诱导治疗期间IL-6、IL-17A和IL-21水平的潜在变化,并评估其与活动性和活动性免疫特征的关系,本研究纳入了28例接受皮质类固醇和免疫抑制剂治疗的狼疮肾炎患者。对人口统计学、临床、血清学资料和疾病活动度进行评估。于第0、12、24周采集血样,采用细胞头阵列法测定血清中IL-17A、IL-6、IL-21的浓度。血清IL-6、IL-17A和IL-21浓度在诱导治疗期间逐渐降低(PPP=0.001)。非缓解组IL-6、IL-17A、IL-21浓度高于缓解组。这些细胞因子的浓度与蛋白尿严重程度(PP=0.020, P=0.045)、ESR (PPP=0.018, P=0.048, P=0.045)呈正相关
{"title":"Induction therapy downregulates the expression of Th17/Tfh cytokines in patients with active lupus nephritis.","authors":"Na Wang,&nbsp;Congcong Gao,&nbsp;Siwan Cui,&nbsp;Yilu Qin,&nbsp;Chunyi Zhang,&nbsp;Peiwen Yi,&nbsp;Xueqi Di,&nbsp;Shengyun Liu,&nbsp;Tianfang Li,&nbsp;Guanmin Gao,&nbsp;Zhaohui Zheng","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To determine the potential changes of IL-6, IL-17A and IL-21 levels during induction therapy, and to assess their relationship with disease activity and immunologic features on patients with active lupus nephritis, twenty-eight patients treated with corticosteroid and immunosuppressants were included in this study. Demographic, clinical, serological data and disease activity were assessed. Blood samples were collected at week 0, 12 and 24, and serum concentrations of IL-17A, IL-6 and IL-21 were measured by cytometric bead array. The serum concentrations of IL-6, IL-17A and IL-21 (<i>P</i><0.001, <i>P</i><0.01, <i>P</i>=0.001, respectively) decreased progressively during induction therapy. Concentration of IL-6, IL-17A and IL-21 was higher in non-remission group than that in remission group. A positive correlation was established between the concentration of these cytokines and the severity of proteinuria (<i>P</i><0.001, <i>P</i>=0.020, <i>P</i>=0.045, respectively), ESR (<i>P</i><0.001), SLEDAI scores (<i>P</i><0.05), and ANA titers (<i>P</i>=0.018, <i>P</i>=0.048, <i>P</i><0.05, respectively). Additionally, ROC curve analysis for IL-6, IL-17A and IL-21 was performed to predict the disease activity. The optimal cutoff level was 5.78 pg/ml, 1.98 pg/ml and 8.59 pg/ml, with AUC=0.809, 0.735 and 0.786. The concentration of IL-6 and IL-21 may be regarded as an indicator for the remission of active lupus nephritis, with cutoff value of 9.12 pg/ml and 11.30 pg/ml, while AUC=0.930 and 0.896. The production of serum IL-6, IL-17A and IL-21 in active LN was dramatically declined during induction therapy, which may improve disease activity while delay disease progression of LN.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"7 4","pages":"67-75"},"PeriodicalIF":0.0,"publicationDate":"2018-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6146154/pdf/ajcei0007-0067.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36517625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of icariin on immunity and its potential application. icariin对免疫的影响及其潜在应用。
Q4 IMMUNOLOGY Pub Date : 2018-06-05
Rong Shen, Ju-Hua Wang

Icariin (ICA) is a major bioactive monomer belonging to flavonoid glycosides attracted from Epimedium, being a classic tonic agent in traditional Chinese medicine. ICA commonly presents multiple effects such as regulating sex hormones, relieving atherosclerosis and antioxidant activity, etc. Recently, more and more studies have demonstrated the application of ICA in autoimmune diseases such as rheumatoid arthritis, bronchial asthma, multiple sclerosis and systemic lupus erythematosus due to its anti-inflammatory. Additionally, ICA also has the anti-tumor activities. Multiple targets and mechanisms of ICA are reported which relates to regulate lymphocytes balance, anti-inflammatory/inflammatory cytokines, signal pathways like NF-kappaβ and Erk-p38-JNK, lymphocyte transcription factors and other targets such as TLRs, STAT and PTEN, etc. In this review, we have updated the advance in this field and these studies have suggested that ICA has a potential to treat immunological and inflammatory diseases.

Icariin(ICA)是从淫羊藿中提取的一种主要的黄酮苷类生物活性单体,是中药中的经典滋补剂。ICA通常具有调节性激素、缓解动脉粥样硬化和抗氧化活性等多种作用。近年来,越来越多的研究表明,ICA具有抗炎作用,可应用于类风湿性关节炎、支气管哮喘、多发性硬化症和系统性红斑狼疮等自身免疫性疾病。此外,ICA还具有抗肿瘤活性。ICA的多个靶点和机制已被报道,涉及调节淋巴细胞平衡、抗炎/炎症细胞因子、信号通路如NF-κβ和Erk-p38-JNK、淋巴细胞转录因子和其他靶点如TLRs、STAT和PTEN等,我们已经更新了该领域的进展,这些研究表明ICA具有治疗免疫和炎症疾病的潜力。
{"title":"The effect of icariin on immunity and its potential application.","authors":"Rong Shen,&nbsp;Ju-Hua Wang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Icariin (ICA) is a major bioactive monomer belonging to flavonoid glycosides attracted from Epimedium, being a classic tonic agent in traditional Chinese medicine. ICA commonly presents multiple effects such as regulating sex hormones, relieving atherosclerosis and antioxidant activity, etc. Recently, more and more studies have demonstrated the application of ICA in autoimmune diseases such as rheumatoid arthritis, bronchial asthma, multiple sclerosis and systemic lupus erythematosus due to its anti-inflammatory. Additionally, ICA also has the anti-tumor activities. Multiple targets and mechanisms of ICA are reported which relates to regulate lymphocytes balance, anti-inflammatory/inflammatory cytokines, signal pathways like NF-kappaβ and Erk-p38-JNK, lymphocyte transcription factors and other targets such as TLRs, STAT and PTEN, etc. In this review, we have updated the advance in this field and these studies have suggested that ICA has a potential to treat immunological and inflammatory diseases.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"7 3","pages":"50-56"},"PeriodicalIF":0.0,"publicationDate":"2018-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055068/pdf/ajcei0007-0050.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41166782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reg3β from cardiomyocytes regulated macrophage migration, proliferation and functional skewing in experimental autoimmune myocarditis. 来自心肌细胞的Reg3β调节实验性自身免疫性心肌炎中巨噬细胞的迁移、增殖和功能倾斜。
Q4 IMMUNOLOGY Pub Date : 2018-04-05 eCollection Date: 2018-01-01
Shanshan Zhou, Han Jiang, Han Wang, Hongxiang Lu, Rong Chen, Huaxi Xu, Zhaoliang Su, Xiaoyi Shao

Macrophages play critical roles in inflammatory initiation, development, resolution and cardiac regeneration of myocarditis. However, Reg3β, as a member of regenerating family of proteins, contributes to dedifferentiation of injury cardiomyocytes as well as cardiac function remodeling. It remains unclear whether Reg3β was associated with macrophages reprogramming during autoimmune myocarditis. Our results showed that Reg3β could effectively recruit macrophages, promoted their proliferation and phagocytosis, and facilitated their polarized into M2 macrophages. Macrophage, especially M1 phenotype contributed to Reg3β production by cardiomyocytes. Our data also indicated that Reg3β was involved in self-protection mechanism following cardiac injury or stress. This suggests that Reg3β might be a critically protective factor of myocardium.

巨噬细胞在心肌炎的炎症发生、发展、消退和心脏再生中起着至关重要的作用。然而,Reg3β作为再生蛋白家族的一员,有助于损伤心肌细胞的去分化和心功能重塑。自身免疫性心肌炎期间,Reg3β是否与巨噬细胞重编程相关尚不清楚。结果表明,Reg3β能有效募集巨噬细胞,促进其增殖和吞噬,并促进其极化为M2巨噬细胞。巨噬细胞,特别是M1表型有助于心肌细胞产生Reg3β。我们的数据还表明Reg3β参与心脏损伤或应激后的自我保护机制。这提示Reg3β可能是心肌的关键保护因子。
{"title":"Reg3β from cardiomyocytes regulated macrophage migration, proliferation and functional skewing in experimental autoimmune myocarditis.","authors":"Shanshan Zhou,&nbsp;Han Jiang,&nbsp;Han Wang,&nbsp;Hongxiang Lu,&nbsp;Rong Chen,&nbsp;Huaxi Xu,&nbsp;Zhaoliang Su,&nbsp;Xiaoyi Shao","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Macrophages play critical roles in inflammatory initiation, development, resolution and cardiac regeneration of myocarditis. However, Reg3β, as a member of regenerating family of proteins, contributes to dedifferentiation of injury cardiomyocytes as well as cardiac function remodeling. It remains unclear whether Reg3β was associated with macrophages reprogramming during autoimmune myocarditis. Our results showed that Reg3β could effectively recruit macrophages, promoted their proliferation and phagocytosis, and facilitated their polarized into M2 macrophages. Macrophage, especially M1 phenotype contributed to Reg3β production by cardiomyocytes. Our data also indicated that Reg3β was involved in self-protection mechanism following cardiac injury or stress. This suggests that Reg3β might be a critically protective factor of myocardium.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"7 2","pages":"8-15"},"PeriodicalIF":0.0,"publicationDate":"2018-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944813/pdf/ajcei0007-0008.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36094484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuroanatomical autonomic substrates of brainstem-gut circuitry identified using transsynaptic tract-tracing with pseudorabies virus recombinants. 利用伪狂犬病毒重组体的跨突触束追踪技术鉴定脑干-肠道回路的神经解剖自律神经基质
Q4 IMMUNOLOGY Pub Date : 2018-04-05 eCollection Date: 2018-01-01
Zhi-Gang He, Quan Wang, Run-Shan Xie, Yong-Sheng Li, Qing-Xiong Hong, Hong-Bing Xiang

To investigate autonomic substrates of brainstem-gut circuitry identified using trans-synaptic tracing with pseudorabies virus (PRV)-152, a strain that expresses enhanced green fluorescent protein, and PRV-614, a strain that expresses enhanced red fluorescent protein, injecting into the rat rectum wall. 3-7 days after PRV-152 injection, spinal cord and brainstem were removed and sectioned, and processed for PRV-152 visualization using immunofluorescence labeling against PRV-152. 6 days after PRV-614 injection, brainstem was sectioned and the neurochemical phenotype of PRV-614-positive neurons was identified using double immunocytochemical labeling against PRV-614 and TPH. We observed that the largest number of PRV-152- or PRV-614-positive neurons was located in the gigantocellular reticular nucleus (Gi), lateral paragigantocellular (LPGi), rostral ventrolateral reticular nucleus (RVL), solitary tract nucleus (Sol), locus coeruleus (LC), raphe magnus nucleus (RMg), subcoeruleus nucleus (SubCD). Double-labeled PRV-614/tryptophan hydroxylase (TPH) neurons were concentrated in the RMg, LPGi and Sol. These brainstem neurons are candidates for relaying autonomic command signals to the gut. The autonomic substrate of brainstem-gut circuitry likely plays an important role in mediating different aspects of stress behaviors.

利用表达增强型绿色荧光蛋白的伪狂犬病毒(PRV)-152株和表达增强型红色荧光蛋白的PRV-614株,向大鼠直肠壁注射经突触追踪技术,研究脑干-肠道回路的自律神经基质。注射 PRV-152 3-7 天后,取出脊髓和脑干并进行切片,然后使用针对 PRV-152 的免疫荧光标记来观察 PRV-152。注射 PRV-614 6 天后,对脑干进行切片,并使用针对 PRV-614 和 TPH 的双重免疫细胞化学标记鉴定 PRV-614 阳性神经元的神经化学表型。我们观察到,数量最多的 PRV-152 或 PRV-614 阳性神经元位于巨网状细胞核(Gi)、外侧副巨网状细胞核(LPGi)、喙腹外侧网状细胞核(RVL)、孤束核(Sol)、小脑室(LC)、剑突大核(RMg)、小脑下核(SubCD)。双标记的 PRV-614/ 色氨酸羟化酶(TPH)神经元集中在 RMg、LPGi 和 Sol。这些脑干神经元是向肠道传递自律神经指令信号的候选神经元。脑干-肠道回路的自律神经基质可能在介导应激行为的不同方面发挥了重要作用。
{"title":"Neuroanatomical autonomic substrates of brainstem-gut circuitry identified using transsynaptic tract-tracing with pseudorabies virus recombinants.","authors":"Zhi-Gang He, Quan Wang, Run-Shan Xie, Yong-Sheng Li, Qing-Xiong Hong, Hong-Bing Xiang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To investigate autonomic substrates of brainstem-gut circuitry identified using trans-synaptic tracing with pseudorabies virus (PRV)-152, a strain that expresses enhanced green fluorescent protein, and PRV-614, a strain that expresses enhanced red fluorescent protein, injecting into the rat rectum wall. 3-7 days after PRV-152 injection, spinal cord and brainstem were removed and sectioned, and processed for PRV-152 visualization using immunofluorescence labeling against PRV-152. 6 days after PRV-614 injection, brainstem was sectioned and the neurochemical phenotype of PRV-614-positive neurons was identified using double immunocytochemical labeling against PRV-614 and TPH. We observed that the largest number of PRV-152- or PRV-614-positive neurons was located in the gigantocellular reticular nucleus (Gi), lateral paragigantocellular (LPGi), rostral ventrolateral reticular nucleus (RVL), solitary tract nucleus (Sol), locus coeruleus (LC), raphe magnus nucleus (RMg), subcoeruleus nucleus (SubCD). Double-labeled PRV-614/tryptophan hydroxylase (TPH) neurons were concentrated in the RMg, LPGi and Sol. These brainstem neurons are candidates for relaying autonomic command signals to the gut. The autonomic substrate of brainstem-gut circuitry likely plays an important role in mediating different aspects of stress behaviors.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"7 2","pages":"16-24"},"PeriodicalIF":0.0,"publicationDate":"2018-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944814/pdf/ajcei0007-0016.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36094485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of HSP90B1 genetic polymorphisms with efficacy of glucocorticoids and improvement of HRQoL in systemic lupus erythematosus patients from Anhui Province. 安徽省系统性红斑狼疮患者HSP90B1基因多态性与糖皮质激素疗效及HRQoL改善的关系
IF 1.4 Q4 IMMUNOLOGY Pub Date : 2018-04-05 eCollection Date: 2018-01-01
Xiu-Xiu Sun, Su-Su Li, Man Zhang, Qiao-Mei Xie, Jian-Hua Xu, Sheng-Xiu Liu, Yuan-Yuan Gu, Fa-Ming Pan, Jin-Hui Tao, Sheng-Qian Xu, Shuang Liu, Jing Cai, De-Guang Wang, Long Qian, Chun-Huai Wang, Li Lian, Hui Xiao, Pei-Ling Chen, Chun-Mei Liang, You-Bing Fang, Qiang Zhou, Hai-Liang Huang, Hong Su, Hai-Feng Pan, Dong-Qing Ye, Yan-Feng Zou

Objective: The aim of this study was to investigate the associations between HSP90B1 gene polymorphisms and the efficacy of glucocorticoids (GCs) and the improvement of health-related quality of life (HRQoL) in Anhui patients with systemic lupus erythematosus (SLE). Method: A total of 305 patients with SLE were recruited to the study. These patients were treated with GCs for 12 weeks and classified into two groups (sensitivity and insensitivity) according to the response to GCs measured by the scores on SLE disease activity index (SLEDAI). The HRQoL of SLE patients were evaluated by 36-item Short Form Health Survey (SF-36) at baseline and 12 weeks respectively. HapMap database and Haploview software were used to select HSP90B1 gene tag single nucleotide polymorphisms (SNPs). Benjamini & Hochberg (BH) method based on false discovery rate (FDR) was used for multiple testing correction. Results: A total of 291 patients were included in final data analysis with 14 patients excluded due to loss to follow-up. Among these patients, 160 patients were sensitive to GCs and 131 patients were insensitive to GCs. Twelve tag SNPs of HSP90B1 gene were selected. The rs12426382 polymorphism was associated with the efficacy of GCs (dominant model: crude OR=0.514, 95% CI=0.321-0.824, P=0.006; adjusted OR=0.513, 95% CI=0.317-0.831, P=0.007). After BH correction, there was no association between rs12426382 polymorphism and efficacy of GCs (PBH =0.084). In haplotype analysis, the haplotype CCCGAACATCCC (OR=2.273, 95% CI=1.248-4.139, P=0.006) and CTGGGACGTTC (OR=0.436, 95% CI=0.208-0.916, P=0.025) showed significant associations with the efficacy of GCs. After corrected by BH method, CCCGAACATCCC was still associated with the efficacy of GCs (PBH =0.048). The rs3794241, rs1165681, rs2722188, rs3794240 and rs10861147 polymorphisms were associated with the improvement of HRQoL among SLE patients (P < 0.05). But no association existed after the correction of BH method (P > 0.05). Conclusions: The results of this study demonstrated that HSP90B1 genetic polymorphisms might be associated with the efficacy of GCs, but not associated with the improvement of HRQoL in Anhui population with SLE.

研究目的本研究旨在探讨安徽系统性红斑狼疮(SLE)患者 HSP90B1 基因多态性与糖皮质激素(GCs)疗效及健康相关生活质量(HRQoL)改善之间的关系。研究方法本研究共招募了 305 名系统性红斑狼疮患者。根据系统性红斑狼疮疾病活动指数(SLEDAI)的评分将这些患者分为两组(敏感组和不敏感组)。系统性红斑狼疮患者的 HRQoL 分别在基线和 12 周时通过 36 项简表健康调查(SF-36)进行评估。使用 HapMap 数据库和 Haploview 软件筛选 HSP90B1 基因标签单核苷酸多态性(SNPs)。采用基于假发现率(FDR)的Benjamini & Hochberg(BH)方法进行多重检验校正。结果共有 291 名患者被纳入最终数据分析,其中 14 名患者因失去随访而被排除。在这些患者中,160 名患者对 GCs 敏感,131 名患者对 GCs 不敏感。HSP90B1 基因的 12 个标记 SNPs 被选中。rs12426382多态性与GCs的疗效相关(显性模型:粗略OR=0.514,95% CI=0.321-0.824,P=0.006;调整OR=0.513,95% CI=0.317-0.831,P=0.007)。经 BH 校正后,rs12426382 多态性与 GCs 的疗效无关联(PBH =0.084)。在单倍型分析中,单倍型 CCCGAACATCCC(OR=2.273,95% CI=1.248-4.139,P=0.006)和 CTGGGACGTTC(OR=0.436,95% CI=0.208-0.916,P=0.025)与 GCs 的疗效有显著相关性。经 BH 方法校正后,CCCGAACATCCC 仍与 GCs 的疗效相关(PBH =0.048)。rs3794241、rs1165681、rs2722188、rs3794240 和 rs10861147 多态性与系统性红斑狼疮患者 HRQoL 的改善相关(P < 0.05)。但经 BH 方法校正后不存在相关性(P > 0.05)。结论本研究结果表明,HSP90B1 基因多态性可能与 GCs 的疗效有关,但与安徽系统性红斑狼疮患者 HRQoL 的改善无关。
{"title":"Association of HSP90B1 genetic polymorphisms with efficacy of glucocorticoids and improvement of HRQoL in systemic lupus erythematosus patients from Anhui Province.","authors":"Xiu-Xiu Sun, Su-Su Li, Man Zhang, Qiao-Mei Xie, Jian-Hua Xu, Sheng-Xiu Liu, Yuan-Yuan Gu, Fa-Ming Pan, Jin-Hui Tao, Sheng-Qian Xu, Shuang Liu, Jing Cai, De-Guang Wang, Long Qian, Chun-Huai Wang, Li Lian, Hui Xiao, Pei-Ling Chen, Chun-Mei Liang, You-Bing Fang, Qiang Zhou, Hai-Liang Huang, Hong Su, Hai-Feng Pan, Dong-Qing Ye, Yan-Feng Zou","doi":"","DOIUrl":"","url":null,"abstract":"<p><p><i>Objective:</i> The aim of this study was to investigate the associations between HSP90B1 gene polymorphisms and the efficacy of glucocorticoids (GCs) and the improvement of health-related quality of life (HRQoL) in Anhui patients with systemic lupus erythematosus (SLE). <i>Method:</i> A total of 305 patients with SLE were recruited to the study. These patients were treated with GCs for 12 weeks and classified into two groups (sensitivity and insensitivity) according to the response to GCs measured by the scores on SLE disease activity index (SLEDAI). The HRQoL of SLE patients were evaluated by 36-item Short Form Health Survey (SF-36) at baseline and 12 weeks respectively. HapMap database and Haploview software were used to select HSP90B1 gene tag single nucleotide polymorphisms (SNPs). Benjamini & Hochberg (BH) method based on false discovery rate (FDR) was used for multiple testing correction. <i>Results:</i> A total of 291 patients were included in final data analysis with 14 patients excluded due to loss to follow-up. Among these patients, 160 patients were sensitive to GCs and 131 patients were insensitive to GCs. Twelve tag SNPs of HSP90B1 gene were selected. The rs12426382 polymorphism was associated with the efficacy of GCs (dominant model: crude <i>OR</i>=0.514, 95% <i>CI</i>=0.321-0.824, <i>P</i>=0.006; adjusted <i>OR</i>=0.513, 95% <i>CI</i>=0.317-0.831, <i>P</i>=0.007). After BH correction, there was no association between rs12426382 polymorphism and efficacy of GCs (<i>P<sub>BH</sub></i> =0.084). In haplotype analysis, the haplotype CCCGAACATCCC (<i>OR</i>=2.273, 95% <i>CI</i>=1.248-4.139, <i>P</i>=0.006) and CTGGGACGTTC (<i>OR</i>=0.436, 95% <i>CI</i>=0.208-0.916, <i>P</i>=0.025) showed significant associations with the efficacy of GCs. After corrected by BH method, CCCGAACATCCC was still associated with the efficacy of GCs (<i>P<sub>BH</sub></i> =0.048). The rs3794241, rs1165681, rs2722188, rs3794240 and rs10861147 polymorphisms were associated with the improvement of HRQoL among SLE patients (<i>P</i> < 0.05). But no association existed after the correction of BH method (<i>P</i> > 0.05). <i>Conclusions:</i> The results of this study demonstrated that HSP90B1 genetic polymorphisms might be associated with the efficacy of GCs, but not associated with the improvement of HRQoL in Anhui population with SLE.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"7 2","pages":"27-39"},"PeriodicalIF":1.4,"publicationDate":"2018-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944816/pdf/ajcei0007-0027.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36094486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The guiding role of bone metabolism test in osteoporosis treatment. 骨代谢检测在骨质疏松症治疗中的指导作用。
IF 1.4 Q4 IMMUNOLOGY Pub Date : 2018-04-05 eCollection Date: 2018-01-01
Wei Zhang, Guo-Ji Yang, Shi-Xian Wu, Dong-Qing Li, Ying-Bo Xu, Cheng-Hong Ma, Jun-Ling Wang, Wei-Wen Chen

Osteoporosis (OP) and osteoporotic fractures are becoming a serious health care issue in the world. Calcium and vitamin D are the basic treatment for osteoporosis. Nonetheless, they do not effectively reduce the incidences of fracture. Currently approved treatments for osteoporosis include selective estrogen receptor modulators (SERMs), bisphosphonates, denosumab, teriparatide, calcitonin and others. However, the appearance of some adverse effects including atypical fracture and breast cancer has limited long-term treatments above mentioned. Therefore, treatment decision should be made on an individual basis, taking into account the relative benefits and risks in different patients. Bone metabolism test helps to assess the patient's condition, which may ultimately lead to therapeutic options and better clinical outcomes.

骨质疏松症(OP)和骨质疏松性骨折正成为全球严重的医疗保健问题。钙和维生素 D 是治疗骨质疏松症的基本药物。然而,它们并不能有效降低骨折的发生率。目前获批的骨质疏松症治疗方法包括选择性雌激素受体调节剂(SERMs)、双磷酸盐、地诺单抗、特立帕肽、降钙素等。然而,非典型骨折和乳腺癌等不良反应的出现限制了上述药物的长期治疗。因此,治疗决定应根据个体情况做出,并考虑到不同患者的相对益处和风险。骨代谢检测有助于评估患者的病情,最终可能会为患者提供治疗方案和更好的临床疗效。
{"title":"The guiding role of bone metabolism test in osteoporosis treatment.","authors":"Wei Zhang, Guo-Ji Yang, Shi-Xian Wu, Dong-Qing Li, Ying-Bo Xu, Cheng-Hong Ma, Jun-Ling Wang, Wei-Wen Chen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Osteoporosis (OP) and osteoporotic fractures are becoming a serious health care issue in the world. Calcium and vitamin D are the basic treatment for osteoporosis. Nonetheless, they do not effectively reduce the incidences of fracture. Currently approved treatments for osteoporosis include selective estrogen receptor modulators (SERMs), bisphosphonates, denosumab, teriparatide, calcitonin and others. However, the appearance of some adverse effects including atypical fracture and breast cancer has limited long-term treatments above mentioned. Therefore, treatment decision should be made on an individual basis, taking into account the relative benefits and risks in different patients. Bone metabolism test helps to assess the patient's condition, which may ultimately lead to therapeutic options and better clinical outcomes.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"7 2","pages":"40-49"},"PeriodicalIF":1.4,"publicationDate":"2018-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944817/pdf/ajcei0007-0040.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36094487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review. SLE治疗过程中霉酚酸酯引起的后部可逆性脑病综合征(PRES):一例报告和回顾
Q4 IMMUNOLOGY Pub Date : 2018-02-05 eCollection Date: 2018-01-01
Lei Zhang, Jian Xu

Posterior reversible encephalopathy syndrome (PRES) is a rare clinical entity associated with systemic lupus erythematosus which characterized by seizure, headache, and altered mental status. The pathophysiology involves subcortical vasogenic edema secondary to hypertension and endothelial damage. PRES is reversible with withdrawal of the offending agent, strict blood pressure control, and treating the underlying disease. We report present here a patient with lupus nephritis who developed PRES following mycophenolate administration.

后部可逆性脑病综合征(PRES)是一种罕见的与系统性红斑狼疮相关的临床症状,其特征为癫痫发作、头痛和精神状态改变。病理生理包括继发于高血压和内皮损伤的皮质下血管源性水肿。通过停用药物、严格控制血压和治疗基础疾病,PRES是可逆的。我们报告一例狼疮性肾炎患者在服用霉酚酸盐后出现PRES。
{"title":"Posterior reversible encephalopathy syndrome (PRES) attributed to mycophenolate mofetil during the management of SLE: a case report and review.","authors":"Lei Zhang,&nbsp;Jian Xu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Posterior reversible encephalopathy syndrome (PRES) is a rare clinical entity associated with systemic lupus erythematosus which characterized by seizure, headache, and altered mental status. The pathophysiology involves subcortical vasogenic edema secondary to hypertension and endothelial damage. PRES is reversible with withdrawal of the offending agent, strict blood pressure control, and treating the underlying disease. We report present here a patient with lupus nephritis who developed PRES following mycophenolate administration.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"7 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2018-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840284/pdf/ajcei0007-0001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35907597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect and safety of diacerein in patients with type 2 diabetes mellitus : a systematic review and meta-analysis. 迪卡瑞林对 2 型糖尿病患者的疗效和安全性:系统综述和荟萃分析。
Q4 IMMUNOLOGY Pub Date : 2017-12-20 eCollection Date: 2017-01-01
Qi Zhang, Junteng Zhou, Yushu Wang, Decai Chen

The Background: Diacerein has been proposed as a treatment option for management of type 2 diabetes due to its anti-inflammatory properties.

Purpose: The aim of this systematic review and meta-analysis of randomized controlled trials (RCTs) is to examine the effect and safety of diacerein in patients with type 2 diabetes.

Data sources and study selection: We searched Pubmed, Embase, and Cochrane Library for RCTs published from database inception to September 2017.

Data extraction and data synthesis: Among 44 studies that were initially identified, four were eligible and were included in the following analysis. Diacerein significantly reduced fasting glycemia [weighted mean differences (WMD) -0.66, 95% confidence interval (95% CI) -1.16 to -0.16] and glycated hemoglobin A1c (HbA1c ) (WMD -0.85, 95% CI -1.44 to -0.26). And the patients with a diacerein supplementation duration of ≤12 weeks had a greater decrease of fasting glycemia and HbA1c than the supplementation duration of >12 weeks. Furthermore, compared with placebo, diacerein revealed a significant increase in the relative risk (RR) of gastrointestinal symptoms (RR=2.50, 95% CI: 1.10 to 5.65), especially in the study subgroup with supplementation duration of >12 weeks (RR=4.01, 95% CI: 2.32 to 6.95).

Limitations: The sample size was relatively small and the duration of included studies was short so that the treatment efficacy and safety for longer duration was unknown.

Conclusions: Although further studies are needed, our findings clearly provide support to the use of diacerein in the clinical management of subjects with type 2 diabetes.

背景:目的:本系统综述和随机对照试验(RCTs)荟萃分析旨在研究2型糖尿病患者使用迪卡瑞林的效果和安全性:我们在Pubmed、Embase和Cochrane图书馆检索了从数据库建立到2017年9月发表的RCT.数据提取和数据综合:在初步确定的44项研究中,有4项符合条件并纳入了以下分析。地屈孕酮能明显降低空腹血糖[加权平均差(WMD)-0.66,95% 置信区间(95% CI)-1.16 至-0.16]和糖化血红蛋白 A1c(HbA1c )(WMD -0.85,95% CI -1.44 至-0.26)。与补充时间大于 12 周的患者相比,补充时间小于 12 周的患者的空腹血糖和 HbA1c 下降幅度更大。此外,与安慰剂相比,迪卡瑞林显著增加了胃肠道症状的相对风险(RR)(RR=2.50,95% CI:1.10 至 5.65),尤其是在补充时间超过 12 周的研究亚组中(RR=4.01,95% CI:2.32 至 6.95):局限性:样本量相对较小,纳入的研究持续时间较短,因此较长时间的疗效和安全性尚不清楚:尽管还需要进一步研究,但我们的研究结果明确支持在 2 型糖尿病患者的临床治疗中使用迪卡瑞林。
{"title":"The effect and safety of diacerein in patients with type 2 diabetes mellitus : a systematic review and meta-analysis.","authors":"Qi Zhang, Junteng Zhou, Yushu Wang, Decai Chen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Background: Diacerein has been proposed as a treatment option for management of type 2 diabetes due to its anti-inflammatory properties.</p><p><strong>Purpose: </strong>The aim of this systematic review and meta-analysis of randomized controlled trials (RCTs) is to examine the effect and safety of diacerein in patients with type 2 diabetes.</p><p><strong>Data sources and study selection: </strong>We searched Pubmed, Embase, and Cochrane Library for RCTs published from database inception to September 2017.</p><p><strong>Data extraction and data synthesis: </strong>Among 44 studies that were initially identified, four were eligible and were included in the following analysis. Diacerein significantly reduced fasting glycemia [weighted mean differences (WMD) -0.66, 95% confidence interval (95% CI) -1.16 to -0.16] and glycated hemoglobin A1c (HbA1c ) (WMD -0.85, 95% CI -1.44 to -0.26). And the patients with a diacerein supplementation duration of ≤12 weeks had a greater decrease of fasting glycemia and HbA1c than the supplementation duration of >12 weeks. Furthermore, compared with placebo, diacerein revealed a significant increase in the relative risk (RR) of gastrointestinal symptoms (RR=2.50, 95% CI: 1.10 to 5.65), especially in the study subgroup with supplementation duration of >12 weeks (RR=4.01, 95% CI: 2.32 to 6.95).</p><p><strong>Limitations: </strong>The sample size was relatively small and the duration of included studies was short so that the treatment efficacy and safety for longer duration was unknown.</p><p><strong>Conclusions: </strong>Although further studies are needed, our findings clearly provide support to the use of diacerein in the clinical management of subjects with type 2 diabetes.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"6 6","pages":"97-106"},"PeriodicalIF":0.0,"publicationDate":"2017-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768895/pdf/ajcei0006-0097.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35750150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of clinical and experimental immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1